Geriatric Medicines Market (By Therapeutics: Analgesic, Antihypertensive, Statins, Antidiabetic, PPI, Anticoagulant, Antipsychotic, Others; By Condition: Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, Respiratory, Others; By Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies: By Route of Administration: Oral, Parenteral, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032


The global geriatric medicines market size was valued at US$ 889 billion in 2022 and is expected to hit around US$ 4111.60 billion by 2032 with a registered CAGR of 16.60% during the forecast period 2023 to 2032.

Geriatric Medicines Market Size 2022 to 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics


U.S. Geriatric Medicines Market  in 2023 2032

The U.S. geriatric medicines market size was reached at US$ 236.47 billion in 2022 and is predicted to touch around US$ 1093.69 billion by 2032 with a CAGR of 16.60% during the forecast period 2023 to 2032.

U.S. Geriatric Medicines Market 2023 To 2032

North America dominated the geriatric medicines market in 2022 with a CAGR of 5.6% from 2023 to 2032. The geriatric medicines market is growing due to rising incidence of chronic disorders which include cancer and diabetes. As per the International Diabetes Federation, approximately 48 million adults in North America have diabetes in 2019, with more than half of these patients being over the age of 65. This trend is expected to continue in the coming years, resulting in increased need for geriatric specific treatments, which will drive the geriatric medicines market in the North America region.

Geriatric Medicines Market Share, By Region, 2021 (%)

Asia-Pacific is expected to develop at the fastest rate 6.5% during the forecast period. The countries such as India, Japan, and China are holds largest share in the Asia-Pacific geriatric medicines market. The factors such as launch of generic medicines, rising disposable income, and expansion of healthcare industry are driving the growth of geriatric medicines market in the region. The growing trend of medical tourism is also creating growth prospects for Asia-Pacific geriatric medicines market.

Growth Factors

The geriatric medicines are prescribed to those people who is age of 65 and above. The therapeutics used for the treatment of geriatrics is antidiabetic, analgesic, antipsychotic, and antihypertensive. The geriatric medicines are used for the treatment of arthritis, cardiovascular disorders, cancer, and neurological disorders.

One of the key factors driving the growth of global geriatric medicines market is the growing population of geriatrics all around the world. As per the UN data from the World Population Prospects for 2019, the number of individuals over the age of 65 is expected to rise from 9% in 2019 to more than 16% by 2050. From 143 million in 2019 to 426 million in 2050, the number of people aged 80 and up is expected to increase. Thus, these figures have positive outlook on the global geriatric medicines market.

Another factor propelling the expansion of global geriatric medicines market is growing prevalence of stroke among geriatric population. In the U.S., stroke is the top of fatalities. As per the Centers for Disease Control and Prevention, one person dies from a stroke every 40 seconds in the U.S. and approximately 795,000 people are affected by stroke each year. There are around 610,000 first or fresh strokes and 185,000 recurrent strokes. This growing number of strokes is supporting the global geriatric medicines market growth and development.

In addition, the growing government initiatives are also boosting the growth of worldwide geriatric medicines market. Moreover, government agencies and public companies are highly investing and providing insurance policies to the consumers. For example, the Federal Long Term Care Insurance Program in the U.S. is a beneficial insurance for the elderly as it covers practically all medical care and costs for persons in the U.S. Similarly, the Long-Term Care Ombudsman Program helps older persons in the U.S. find residential care facilities, nursing homes, and assisted living settings.

The government is also providing tax benefits to the manufacturers of geriatric medicines. Those benefits are incentives and subsidies. This factor is supporting the growth of global geriatric medicines market. The market players operating in global geriatric medicines market are also adopting unique strategies for creating their position in the market. The non-profit organizations are collaborating with market players for providing drugs and medications to the geriatric people who are in need. This factor is contributing towards the growth of global geriatric medicines market.

Besides this, the major market players are adopting strategies such as joint venture, partnership, product launch, business expansion, merger, and acquisition. All these strategies help market players to reach maximum number of people this assist in the growth of revenue and sales share all around the world.

Report Scope of the Geriatric Medicines Market

Report Coverage Details
Market Size by 2032 USD 4111.60 Billion
Growth Rate from 2023 to 2032

CAGR of 16.60%

Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Therapeutics, Condition, Distribution Channels, Route of Administration, Geography
Companies Mentioned GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck & Company Inc., Abbott Laboratories Inc., Eli Lilly & Company, AstraZeneca PLC

 

Therapeutics Insights

The analgesics segment dominated the geriatric medicines market in 2022. The demand for analgesics is growing due to the surge in number of pain related disorders among old people. The bones of geriatric people are quite weak as compared to young population. The other factors driving the growth of analgesics segment is the growing drugs and medicines sales through over the counter (OTC) platforms and sales of prescription drugs.

The antidiabetic segment is expected to witness strong growth during forecast period. Diabetes affects a large percentage of the elderly. Around 20% of the population is affected by this disease by the age of 75. Diabetes in senior persons has a different metabolic profile than diabetes in younger patients, necessitating a different strategy to treatment. Due to all these factors, the antidiabetic segment is expanding at a rapid pace.

Condition Insights

The cardiovascular segment dominated the geriatric medicines market in 2022. Cardiovascular disorders are more common in the elderly and those over the age of 65. In geriatric population, age is an individual cause of cardiovascular diseases, although other variables such as obesity and diabetes augment these risks. These factors have been shown to adversely affect and worsen cardiac risk factors linked to old age.

Geriatric Medicines Market Share, By Condition, 2022 (%)

The cancer segment is projected to hit remarkable growth from 2023 to 2032. Cancer risk rises rapidly with the age, without a fact. People aged 65 and up account for almost 60% of all cancer cases. In addition, this stage accounts roughly 70% of cancer related mortality. As a result, cancer is an old age disorder. Given the rise in cancer incidence and standard of living among the senior population, a unique approach to the treatment and longevity of geriatric cancer patients is required.

Key Developments

  • The U.S. FDA granted orphan drug designation to Nomacopan, a biopharmaceutical firm focuses on novel therapies to treat and diagnose orphan autoimmune and inflammatory illnesses, in September 2019, propelling market growth.
  • Merck & Co. Inc. released preliminary findings from its Molunpiravir anti-COVID-19 drug clinical trials in October 2021. According to the data, giving this antiviral to individuals with moderate symptoms cut their risk of being admitted to the hospital in half. This medicine resulted in a complete recovery of all who were given it.
  • Repatha was launched in Japan by Amgen Inc. and Astellas Pharma Inc. in April 2016. Repatha is a PCSK9 inhibitor used to treat patients with hypercholesterolemia who have a significant risk of heart diseases.
  • Pfizer declared the acquisition of Trillium Therapeutics, a clinical stage immune oncology business in August 2021. The agreement will aid in the advancement of cancer treatment. The acquisition is expected to be valued $2.26 billion, according to Pfizer.

Some of the prominent players in the global geriatric medicines market include:

  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Merck & Company Inc.
  • Abbott Laboratories Inc.
  • Eli Lilly & Company
  • AstraZeneca PLC

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Therapeutics

  • Analgesic
  • Antihypertensive
  • Statins
  • Antidiabetic
  • PPI
  • Anticoagulant
  • Antipsychotic
  • Others

By Condition

  • Cardiovascular
  • Arthritis
  • Neurological
  • Cancer
  • Osteoporosis
  • Respiratory
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of geriatric medicines market?
The geriatric medicines market size was reached at US$ 889 billion in 2022 and is anticipated to rake around US$ 4111.60 billion by 2032.
What will be the CAGR of global geriatric medicines market?
The geriatric medicines market is expected to grow at a CAGR of 16.60% over the forecast period 2023 to 2032.
Who are the major players operating in the geriatric medicines market?
The major players operating in the geriatric medicines market are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck & Company Inc., Abbott Laboratories Inc., Eli Lilly & Company, and AstraZeneca PLC.
Which are the driving factors of the geriatric medicines market?
One of the key factors driving the growth of global geriatric medicines market is the growing population of geriatrics all around the world. Another factor propelling the expansion of global geriatric medicines market is growing prevalence of stroke among geriatric population.
Which region will lead the global geriatric medicines market?
North America region will lead the global geriatric medicines market over the forecast period 2023 to 2032.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample